CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.

Autor: Mackensen A; University Hospital Erlangen, Department of Internal Medicine 5, Hematology/Oncology, Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Haanen JBAG; Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, the Netherlands.; Leiden University Medical Center, Department of Oncology, Leiden, the Netherlands., Koenecke C; Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany., Alsdorf W; University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, Hamburg, Germany., Wagner-Drouet E; University Medical Center Mainz, 3rd Medical Department, Hematology and Oncology, Mainz, Germany., Borchmann P; University Hospital of Cologne, Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Cologne, Germany., Heudobler D; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Regensburg, Germany., Ferstl B; University Hospital Erlangen, Department of Internal Medicine 5, Hematology/Oncology, Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Klobuch S; Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, the Netherlands., Bokemeyer C; University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, Hamburg, Germany., Desuki A; University Medical Center Mainz, 3rd Medical Department, Hematology and Oncology, Mainz, Germany., Lüke F; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Regensburg, Germany., Kutsch N; University Hospital of Cologne, Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Cologne, Germany., Müller F; University Hospital Erlangen, Department of Internal Medicine 5, Hematology/Oncology, Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Smit E; Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, the Netherlands., Hillemanns P; Hannover Medical School, Department of Gynecology and Obstetrics, Hannover, Germany., Karagiannis P; University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, Hamburg, Germany., Wiegert E; Bexon Clinical Consulting, Upper Montclair, NJ, USA., He Y; BioNTech SE, Mainz, Germany., Ho T; BioNTech US, Cambridge, MA, USA., Kang-Fortner Q; BioNTech US, Cambridge, MA, USA., Schlitter AM; BioNTech SE, Mainz, Germany., Schulz-Eying C; BioNTech SE, Mainz, Germany., Finlayson A; BioNTech SE, Mainz, Germany., Flemmig C; BioNTech SE, Mainz, Germany., Kühlcke K; BioNTech Innovative Manufacturing Services GmbH, Idar-Oberstein, Germany., Preußner L; BioNTech SE, Mainz, Germany., Rengstl B; BioNTech SE, Mainz, Germany.; BioNTech Cell & Gene Therapies GmbH, Mainz, Germany., Türeci Ö; BioNTech SE, Mainz, Germany.; BioNTech US, Cambridge, MA, USA.; BioNTech Innovative Manufacturing Services GmbH, Idar-Oberstein, Germany.; BioNTech Cell & Gene Therapies GmbH, Mainz, Germany., Şahin U; BioNTech SE, Mainz, Germany. Ugur.Sahin@biontech.de.; BioNTech US, Cambridge, MA, USA. Ugur.Sahin@biontech.de.; BioNTech Innovative Manufacturing Services GmbH, Idar-Oberstein, Germany. Ugur.Sahin@biontech.de.; BioNTech Cell & Gene Therapies GmbH, Mainz, Germany. Ugur.Sahin@biontech.de.

Publikováno v: Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2844-2853. Date of Electronic Publication: 2023 Oct 23.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors.

Autor: Udvorková, Natália, Fekiačová, Adriana, Majtánová, Kristína, Mego, Michal, Kučerová, Lucia

Publikováno v: American Journal of Physiology: Cell Physiology; Aug2024, Vol. 327 Issue 2, pC362-C371, 10p